Skip to content

Biomarin Pharmaceutical

US · BMRN #1379 by market cap Listed 1970
55.20 -1.02 -1.81%
Live - 5344 symbols - heartbeat 90s ago · 2026-10-08 07:00
Pre-market 55.05 -0.27%
After-hours 55.55 +0.63%
Market cap
10.69B
P/B
1.69
EPS
1.80
Reader sentiment Are you bullish or bearish on BMRN?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    William Blair Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating
    Market Newswire · 2026/8/19
  • Rating change
    A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $70 to $124
    Market Newswire · 2026/9/1
  • Rating change
    Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $88
    Market Newswire · 2026/8/17
  • Rating change
    Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $90
    Market Newswire · 2026/9/2
  • Rating change
    Stifel Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $70
    Market Newswire · 2026/8/31
  • Rating change
    Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $88
    Market Newswire · 2026/8/26
  • Citi Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
    Market Newswire · 2026/9/15
  • Rating change
    A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $86 to $120
    Market Newswire · 2026/8/19
  • Rating change
    Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $105
    Market Newswire · 2026/8/10
  • J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $86
    Market Newswire · 2026/9/21
  • BMO Capital Upgrades Biomarin Pharmaceutical(BMRN.US) to Buy Rating, Raises Target Price to $97
    Market Newswire · 2026/9/16
  • Rating change
    Cantor Fitzgerald Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $86
    Market Newswire · 2026/9/2
  • Guggenheim Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $86
    Market Newswire · 2026/9/18
  • Rating change
    TD Cowen Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/8/21
  • Rating change
    CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $114
    Market Newswire · 2026/8/20
  • Rating change
    A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $62 to $124
    Market Newswire · 2026/8/8
  • Morgan Stanley Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $124
    Market Newswire · 2026/9/16
  • Rating change
    Wells Fargo Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $80
    Market Newswire · 2026/9/11
  • Rating change
    CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $114
    Market Newswire · 2026/8/10
  • Rating change
    Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $111
    Market Newswire · 2026/8/17

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.